Feature article: Hardman & Co Healthcare Index - Review of 2022
The main function of the HHI is to monitor the performance, and to highlight the attractiveness, of life sciences investments over the long term, and to try to identify those stocks that have disruptive technologies that consistently allow them to outperform both the index and the markets. Many of the 53 constituents of the index are high-risk, still being in the development stage, with micro-capitalisations and a long way from sales and profitability. Despite this, some companies can still make extremely attractive returns for investors. However, although pharmaceutical, biotech and healthcare industries have defensive qualities, they are not immune from global economics.

10 Jan 2023
Hardman & Co Monthly: January 2023
Volta Finance Limited (VTA:LON), 500 | Tissue Regenix Group plc (TRX:LON), 0.6 | Surface Transforms PLC (SCE:LON), 32.0 | Shield Therapeutics Plc (STX:LON), 6.0 | Real Estate Credit Investments Limited (RECI:LON), 134 | Advanced Oncotherapy Plc (AVO:LON), 3.2 | Arbuthnot Banking Group PLC (ARBB:LON), 905 | Fidelity Asian Values PLC GBP (FAS:LON), 501 | Fidelity China Special Situations PLC (FCSS:LON), 248 | Fidelity European Trust PLC GBP (FEV:LON), 328 | Fidelity Japan Trust PLC (FJV:LON), 172 | Fidelity Special Values PLC GBP (FSV:LON), 264 | ICG Enterprise Trust PLC GBP (ICGT:LON), 1,007 | International Biotechnology Trust PLC (IBT:LON), 646 | Oakley Capital Investments Ltd Registered (OCI:LON), 456 | Pantheon Resources plc (PANR:LON), 25.0
-
-
-
Brian Moretta | Martin Hall | Mike Foster | Mark Thomas
-
32 pages
-

Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Hardman & Co Monthly: January 2023
Volta Finance Limited (VTA:LON), 500 | Tissue Regenix Group plc (TRX:LON), 0.6 | Surface Transforms PLC (SCE:LON), 32.0 | Shield Therapeutics Plc (STX:LON), 6.0 | Real Estate Credit Investments Limited (RECI:LON), 134 | Advanced Oncotherapy Plc (AVO:LON), 3.2 | Arbuthnot Banking Group PLC (ARBB:LON), 905 | Fidelity Asian Values PLC GBP (FAS:LON), 501 | Fidelity China Special Situations PLC (FCSS:LON), 248 | Fidelity European Trust PLC GBP (FEV:LON), 328 | Fidelity Japan Trust PLC (FJV:LON), 172 | Fidelity Special Values PLC GBP (FSV:LON), 264 | ICG Enterprise Trust PLC GBP (ICGT:LON), 1,007 | International Biotechnology Trust PLC (IBT:LON), 646 | Oakley Capital Investments Ltd Registered (OCI:LON), 456 | Pantheon Resources plc (PANR:LON), 25.0
- Published:
10 Jan 2023 -
Author:
Brian Moretta | Martin Hall | Mike Foster | Mark Thomas -
Pages:
32 -
Feature article: Hardman & Co Healthcare Index - Review of 2022
The main function of the HHI is to monitor the performance, and to highlight the attractiveness, of life sciences investments over the long term, and to try to identify those stocks that have disruptive technologies that consistently allow them to outperform both the index and the markets. Many of the 53 constituents of the index are high-risk, still being in the development stage, with micro-capitalisations and a long way from sales and profitability. Despite this, some companies can still make extremely attractive returns for investors. However, although pharmaceutical, biotech and healthcare industries have defensive qualities, they are not immune from global economics.